In CRC patients, the mutation state of KRAS and BRAF is consistent in situ with CRC and corresponding metastatic foci, and the effect of chemotherapeutic drugs such as antiepidermal growth factor receptor antibodies, cetuximab, and panitumumab is also affected by the mutation state of KRAS and BRAF [21]. This evidence concerns the gene KRAS and colorectal carcinoma.